Mesencephalic and striatal protein profiles in mice over-expressing glucose-6-phosphate dehydrogenase in dopaminergic neurons

Journal of Proteomics

Volumn 73, Issue 9, 2010, Pages 1747-1757

  Romero Ruiz, Antonio ^a   Mejías, Rebeca ^a   Díaz Martín, Juan ^a,b   López Barneo, José ^a,b   Gao, Lin ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Antioxidant defense; Glucose 6 phosphate dehydrogenase; Parkinson's disease; Proteomics; Transgenic mice

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; DOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DETOXIFICATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE OVEREXPRESSION; MESENCEPHALON; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; GENE EXPRESSION PROFILING; GENETICS; INTOXICATION; MASS SPECTROMETRY; METABOLISM; NERVE CELL; PARKINSONISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; CORPUS STRIATUM; DOPAMINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; GLUCOSEPHOSPHATE DEHYDROGENASE; MESENCEPHALON; MICE; MICE, TRANSGENIC; MPTP POISONING; NEURONS; PARKINSONIAN DISORDERS; POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTANTIA NIGRA;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77954660152     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.05.014     Document Type: Article

References (51)

1. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
2. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53(Suppl 3):S26-S36. (discussion S-8).
3. Tansey M.G., Frank-Cannon T.C., McCoy M.K., Lee J.K., Martinez T.N., McAlpine F.E., et al. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?. Front Biosci 2008, 13:709-717.
4. Olanow C.W. The pathogenesis of cell death in Parkinson's disease-2007. Mov Disord 2007, 22(Suppl 17):S335-S342.
5. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744-1754.
6. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
7. Wu Y.R., Wang C.K., Chen C.M., Hsu Y., Lin S.J., Lin Y.Y., et al. Analysis of heat-shock protein 70 gene polymorphisms and the risk of Parkinson's disease. Hum Genet 2004, 114:236-241.
8. Scherzer C.R., Eklund A.C., Morse L.J., Liao Z., Locascio J.J., Fefer D., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 2007, 104:955-960.
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
10. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
11. Ghribi O., Herman M.M., Pramoonjago P., Savory J. MPP+ induces the endoplasmic reticulum stress response in rabbit brain involving activation of the ATF-6 and NF-kappaB signaling pathways. J Neuropathol Exp Neurol 2003, 62:1144-1153.
12. Pandolfi P.P., Sonati F., Rivi R., Mason P., Grosveld F., Luzzatto L. Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J 1995, 14:5209-5215.
13. Tian W.N., Braunstein L.D., Apse K., Pang J., Rose M., Tian X., et al. Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol 1999, 276:C1121-C1131.
14. Kletzien R.F., Harris P.K., Foellmi L.A. Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J 1994, 8:174-181.
15. Salvemini F., Franze A., Iervolino A., Filosa S., Salzano S., Ursini M.V. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J Biol Chem 1999, 274:2750-2757.
16. Vulliamy T., Mason P., Luzzatto L. The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet 1992, 8:138-143.
17. Abraham S., Soundararajan C.C., Vivekanandhan S., Behari M. Erythrocyte antioxidant enzymes in Parkinson's disease. Indian J Med Res 2005, 121:111-115.
18. Gao L., Mir P., Diaz-Corrales F.J., Mejias R., Carrillo F., Vime P.J., et al. Glucose-6-phosphate dehydrogenase activity in Parkinson's disease. J Neurol 2008, 255:1850-1851.
19. Lee Y.M., Park S.H., Shin D.I., Hwang J.Y., Park B., Park Y.J., et al. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J Biol Chem 2008, 283:9986-9998.
20. Mejias R., Villadiego J., Pintado C.O., Vime P.J., Gao L., Toledo-Aral J.J., et al. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J Neurosci 2006, 26:4500-4508.
21. Bautista J.M., Mason P.J., Luzzatto L. Purification and properties of human glucose-6-phosphate dehydrogenase made in E. coli. Biochim Biophys Acta 1992, 1119:74-80.
22. Pascual A., Romero-Ruiz A., Lopez-Barneo J. Differential proteomic analysis of adrenal gland during postnatal development. Proteomics 2009, 9:2946-2954.
23. Shevchenko A., Wilm M., Vorm O., Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858.
24. Ursini M.V., Parrella A., Rosa G., Salzano S., Martini G. Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress. Biochem J 1997, 323(Pt 3):801-806.
25. De Simoni S., Goemaere J., Knoops B. Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+. Neurosci Lett 2008, 433:219-224.
26. Kitsou E., Pan S., Zhang J., Shi M., Zabeti A., Dickson D.W., et al. Identification of proteins in human substantia nigra. Proteomics Clin Appl 2008, 2:776-782.
27. Werner C.J., Heyny-von Haussen R., Mall G., Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci 2008, 6:8.
28. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics 2004, 4:3943-3952.
29. Tretter L., Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci 2000, 20:8972-8979.
30. Smith S.R., Cooperman S., Lavaute T., Tresser N., Ghosh M., Meyron-Holtz E., et al. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci 2004, 1012:65-83.
31. Smeyne M., Boyd J., Raviie Shepherd K., Jiao Y., Pond B.B., Hatler M., et al. GSTpi expression mediates dopaminergic neuron sensitivity in experimental parkinsonism. Proc Natl Acad Sci U S A 2007, 104:1977-1982.
32. Mandel S., Grunblatt E., Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J Neural Transm Suppl 2000, 117-124.
33. Chen S., Brown I.R. Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperones 2007, 12:51-58.
34. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005, 1053:356-375.
35. Andringa G., Bol J.G., Wang X., Boekel A., Bennett M.C., Chase T.N., et al. Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain. Neuropathol Appl Neurobiol 2006, 32:157-169.
36. Park J.W., Moon C., Yun S., Kim S.Y., Bae Y.C., Chun M.H., et al. Differential expression of heat shock protein mRNAs under in vivo glutathione depletion in the mouse retina. Neurosci Lett 2007, 413:260-264.
37. Chinni S.R., Brenz M., Shisheva A. Modulation of GDP-dissociation inhibitor protein membrane retention by the cellular redox state in adipocytes. Exp Cell Res 1998, 242:373-380.
38. Villa R.F., Arnaboldi R., Ghigini B., Gorini A. Parkinson-like disease by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) toxicity in Macaca fascicularis: synaptosomal metabolism and action of dihydroergocriptine. Neurochem Res 1994, 19:229-236.
39. Jayakar S.S., Dikshit M. AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. Int J Neurosci 2004, 114:695-734.
40. Lowenstein C.J., Tsuda H. N-ethylmaleimide-sensitive factor: a redox sensor in exocytosis. Biol Chem 2006, 387:1377-1383.
41. Wang Y., Floor E. Hydrogen peroxide inhibits the vacuolar H+-ATPase in brain synaptic vesicles at micromolar concentrations. J Neurochem 1998, 70:646-652.
42. Lee H.J., Suk J.E., Bae E.J., Lee J.H., Paik S.R., Lee S.J. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008, 40:1835-1849.
43. Schevzov G., Bryce N.S., Almonte-Baldonado R., Joya J., Lin J.J., Hardeman E., et al. Specific features of neuronal size and shape are regulated by tropomyosin isoforms. Mol Biol Cell 2005, 16:3425-3437.
44. Bota D.A., Davies K.J. Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism. Nat Cell Biol 2002, 4:674-680.
45. Lu B., Yadav S., Shah P.G., Liu T., Tian B., Pukszta S., et al. Roles for the human ATP-dependent Lon protease in mitochondrial DNA maintenance. J Biol Chem 2007, 282:17363-17374.
46. Gnerer J.P., Kreber R.A., Ganetzky B. Wasted away, a Drosophila mutation in triosephosphate isomerase, causes paralysis, neurodegeneration, and early death. Proc Natl Acad Sci U S A 2006, 103:14987-14993.
47. Ralser M., Wamelink M.M., Kowald A., Gerisch B., Heeren G., Struys E.A., et al. Dynamic rerouting of the carbohydrate flux is key to counteracting oxidative stress. J Biol 2007, 6:10.
48. Ichimura T., Isobe T., Okuyama T., Takahashi N., Araki K., Kuwano R., et al. Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc Natl Acad Sci U S A 1988, 85:7084-7088.
49. Kawamoto Y., Akiguchi I., Nakamura S., Honjyo Y., Shibasaki H., Budka H. 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 2002, 61:245-253.
50. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., et al. Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 1999, 19:5782-5791.
51. Licker V., Kovari E., Hochstrasser D.F., Burkhard P.R. Proteomics in human Parkinson's disease research. J Proteomics 2009, 73:10-29.